Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 271 AL 285

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease

Rosén C, Zetterberg H.

Curr Opin Psychiatry. 2013 May;26(3):276-82. doi: 10.1097/YCO.0b013e32835f6747.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21.

Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process

Stefani A, Olivola E, Stampanoni Bassi M, Pisani V, Imbriani P, Pisani A, Pierantozzi M.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):538-46. doi: 10.2174/1871527311312040016.

[New risk genes for Alzheimer's disease--biomarkers predicting the disease?]

Hiltunen M, Haapasalo A, Soininen H.

Duodecim. 2013;129(6):583-8.

Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease

Schmitt A, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):271-2. doi: 10.1007/s00406-013-0409-0.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

Is there a causal link between inflammation and dementia?

Enciu AM, Popescu BO.

Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.

Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies

Chen Z, Zhong C.

Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11.

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D.

Food Chem Toxicol. 2013 Nov;61:209-14. doi: 10.1016/j.fct.2013.07.013. Epub 2013 Jul 16.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

Imaging markers for Alzheimer disease: which vs how

Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C; ISTAART's NeuroImaging Professional Interest Area.

Neurology. 2013 Jul 30;81(5):487-500. doi: 10.1212/WNL.0b013e31829d86e8.

Clinical pharmacology of novel anti-Alzheimer disease modifying medications

Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, Salomone S.

Curr Top Med Chem. 2013;13(15):1853-63. doi: 10.2174/15680266113139990141.

Amyloid imaging: the court of public opinion

Lerner AJ.

Neurology. 2013 Sep 24;81(13):1108-9. doi: 10.1212/WNL.0b013e3182a55fe3. Epub 2013 Aug 21.

Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans

Deguil J, Ravasi L, Auffret A, Babiloni C, Bartres Faz D, Bragulat V, Cassé-Perrot C, Colavito V, Herrero Ezquerro MT, Lamberty Y, Lanteaume L, Pemberton D, Pifferi F, Richardson JC, Schenker E, Blin O, Tarragon E, Bordet R.

Drug Discov Today Technol. 2013 Sep;10(3):e329-42. doi: 10.1016/j.ddtec.2013.03.003.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias